A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

Abstract Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2‐year efficacy and safety of nilotinib and their rel...

Full description

Bibliographic Details
Main Authors: Junghoon Shin, Youngil Koh, Seo Hyun Yoon, Joo‐Youn Cho, Dae‐Young Kim, Kyoo‐Hyung Lee, Hyeong‐Joon Kim, Jae‐Sook Ahn, Yeo‐Kyeoung Kim, Jinny Park, Sang‐Kyun Sohn, Joon Ho Moon, Yoo Jin Lee, Seonghae Yoon, Jeong‐Ok Lee, June‐Won Cheong, Kyoung Ha Kim, Sung‐Hyun Kim, Hoon‐Gu Kim, Hawk Kim, Seung‐Hyun Nam, Young Rok Do, Sang‐Gon Park, Seong Kyu Park, Sung Hwa Bae, Hun Ho Song, Dong‐Yeop Shin, Doyeun Oh, Min Kyoung Kim, Chul Won Jung, Seonyang Park, Inho Kim
Format: Article
Language:English
Published: Wiley 2018-05-01
Series:Cancer Medicine
Subjects:
CML
molecular response
nilotinib
prognosis
Online Access:https://doi.org/10.1002/cam4.1450

Internet

https://doi.org/10.1002/cam4.1450

Similar Items